Navigation Links
Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
Date:9/25/2007

ng to guide people to healthier nutrition that fits with their genetics."

To view the published paper please visit http://nutritionjrnl.com/inpress

For more information on Interleukin please visit http://www.ilgenetics.com

About the Study

This was a randomized, placebo controlled clinical trial designed to test effects of botanical formulations versus placebo for reduction of inflammatory chemicals in individuals who are genetically predisposed to over-produce inflammation. Healthy adults with elevated C-reactive protein (CRP) levels were stratified into genetic groups based on being either positive or negative for the IL-1 gene variations that are associated with over-expression of IL-1 Beta and increased risk for coronary artery disease events, such as a myocardial infarction. The IL-1 positive and negative subjects were randomized to either a botanical formulation or placebo. The botanical formulation included rose hips, a blueberry and blackberry mixture, and a grape vine extract. This formulation was developed by Access Business Group International LLC by screening hundreds of botanical extracts for their ability to inhibit IL-1 Beta or CRP production. After 12 weeks of dosing with the botanical formulation, the IL-1 Beta gene expression by stimulated peripheral blood mononuclear cells was significantly lower than baseline and significantly lower than placebo in both IL-1 genotype positive and negative subjects. Over the 12 week treatment period, the mean reduction in IL-1 Beta gene expression with the botanical was greater in genotype positive than in the genotype negative subjects. In IL-1 genotype positive subjects, significantly more subjects achieved a reduction in CRP with the botanical mixture than with the placebo. No CRP effect was observed in the IL-1 genotype negative subjects.

About Interleukin

Inter
'/>"/>

SOURCE Interleukin Genetics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
6. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
7. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
8. Researchers Identify New Genetic Risk Factors for Type 2 Diabetes
9. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
10. Myriad Genetics Presents Tumor Origin Technology at AACR
11. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2008)...EAPOLIS, July 22 /- Nonin Medical, a ...tions for more than 20 years, has entered,the clin...y to measure,regional oxygen saturation. Today,s m...continuous monitoring of the regional blood oxygen...esting data and outcomes from an ongoing clinical ...
(Date:7/22/2008)...DA Meeting to Discuss Development Plan Completed S...-FirstCall/ -- Amarin Corporation,plc (NASDAQ: AM... with,officials at the U.S. Food and Drug Administ...elop AMR101 for the treatment of,hypertriglyceride...roceeding to Phase 3 with AMR101 in hypertriglycer...
(Date:7/22/2008)...-of-the-Art PET Study Confirms Tyrima Exhibits Exc...erties - - Results Support Initiation of Pha...N.C., July 22 /- CeNeRx BioPharma,In...cializing innovative,treatments for diseases of th... advance its lead candidate Tyrima(TM) into Phase ...
(Date:7/22/2008)...eoffrey Allan Will Stress the Importance to Patien...cs Approval Pathway, RICHMOND, Va., July 22 /PRNe... a developer of follow-on biologics and biopharmac...D., CEO of Insmed, will present at a,Congressional...e,significant need for establishing an approval pa...
Breaking Medicine Technology:Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Serum sodium predicts mortality 10 times higher in PAH patients 21781 1Serum sodium predicts mortality 10 times higher in PAH patients 21781 2New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 1New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 2New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 3New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 4New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 5New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 6New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 71 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9 11 21776 11 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9 11 21776 2Membrane complexes take flight 5975 1Membrane complexes take flight 5975 2
(Date:7/25/2008)... firm represents Pickerington man who contracted E... Kroger store , Columbus,...onaheyohioinjurylawyers.com [The Donahey Law Firm... central Ohio, has filed a product liability lawsu...ainst The Kroger Co., in connection with an E. col...
(Date:7/24/2008)...ital facility on Sand Canyon Avenue , ...08 -- Hoag Memorial Hospital Presbyterian has reac...l Estate Investment Trust headquartered in Long Be... Sand Canyon Avenue near the 405 freeway in Irvine...d by Tenet Healthcare Corporation (NYSE: THC) as I...
(Date:7/24/2008)...stCall/ -- ev3 Inc. (Nasdaq:,EVVV) today announced...and,year-to-date financial results. ev3 will now r...ancial results on Monday, July 28, 2008, after reg... a conference call and webcast at 7:30 a.m.,Centra...9, 2008. ev3,management will review its second qua...
(Date:7/24/2008)...ine Annual Report Experience it at http:/...f., July 24 /PRNewswire/ -- Are you an e-patient?,...users go online for,health information. Thanks to ...re personal health experiences, shop for health ca...Go to http://SutterHealth.org/annualreport ,and y...
Breaking Medicine News(10 mins):Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4
...edouble its efforts in the fight against HIV and A...tions program on HIV/AIDS, comes after Fiji's Mini...e in the number of people living with HIV and AIDS... The figures show that there were 36 new cases in...
...zil, Paraguay and Bolivia after an outbreak of den...fall //this season as a cause of the unusually rap...ncommonly warm weather has boosted the population ...the disease. Globally, it infects 50 million peo...
...Ministry of Health reported 789 suspected cases in...he country. // Ouargaye district has an attack rat...istricts, Banfora, Batie and Sapouy are in the ale...specimens have tested positive for Neisseria menin...
...als in the brain of mice were augmented, condition...ate in such animals. //This was reported by resear...alifornia. This finding could throw light in the ...cording to this study published in Nature, a combi...
Other Medicine News:
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
...w Binding, Graduated Pipet Tips - 0.5l - 10 L. Des... and protein binding. Non-reactive. Beveled and re...tion. RNAse & DNAse free. AVR100S is the Sterile R...0 is the Cell Rack packaged 96 tips/rack and 10 ra...
Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili
Like all Gilson disposable pipette tips, TowerPacks are available in a sterilized version. Each Sterilized TowerPack is individually wrapped in medical device-quality plastic to help protect tips fro
Medicine Products: